Standard management of SAH focuses on:

  • blood pressure control and maintenance of normovolemia
  • prevention and treatment of vasospasms
  • elimination of the aneurysm from the circulation
  • prevention and management of complications  (both intra- and extracerebral)

General therapy and patient monitoring

  • the initial management of patients with SAH is directed toward stabilizing the patient
  • perform a basic neurological examination, assess the level of consciousness (LOC), airway, breathing, and circulation (ABCs)
    • endotracheal intubation should be performed in patients presenting with coma, decreased level of consciousness, inability to protect the airway, or increased intracranial pressure (ICP)
    • patients with signs of increased ICP or herniation should be hyperventilated (target pCO2 of 30-35 mm Hg)
  • while there are some specifics in the conservative treatment of SAH (see tabs), the principles of general stroke management and management of intracranial hypertension apply
Treatment Regimen
  • admission to the intensive care unit (ICU)
  • initially, strict bed rest with the head kept elevated at 30° (optimal venous drainage ⇒ ↓ ICP )
  • start prevention of constipation (especially in patients with unsecured aneurysms)
  • early rehabilitation, after the ruptured aneurysm is secured, is reasonable to improve functional outcome  (AHA/ASA 2023)
  • actively search for post-aSAH depression and anxiety; if present, psychotherapy and pharmacotherapy are recommended
  • the use of a validated screening tool in the post-acute period is useful for identifying cognitive dysfunction
  • perform repeated neurologic examinations, including evaluation of the level of consciousness (LOC)
  • monitor hemodynamic and respiratory parameters or initiate extended neuromonitoring
  • monitor and treat hyponatremia → see here
  • monitor for cardiac complications see here
  • use TCD/TCCD for monitoring vasospasms (see below)
  • detect and treat other SAH complications
Blood pressure
  • start noninvasive continuous BP monitoring immediately; for severe SAH or fluctuating blood pressure, invasive monitoring is preferred
  • BP control in SAH is complex;  rationale exists for both lowering BP (↓ rebleeding risk ) and increasing BP (↓ risk of DID)
  • with an untreated source of bleeding, aim to maintain SBP ≤ 130-140 mm Hg
    • postoperatively 150-175 mm Hg   (⇒  ↑ CPP)
  • in the presence of cerebral vasospasms and a secured aneurysm, the target SBP is approx. 180-220 mmHg to improve cerebral perfusion
  • excessive and rapid BP correction may be harmful (↓CPP ⇒ risk of ischemia due to vasospasm)
  • avoid nitrates if possible, as they may increase intracranial pressure (ICP)
Analgesics, anxiolytics
  • analgesics, often opioids, are needed to contain severe headache
  • corticosteroids can be used successfully in the treatment of aseptic meningitis (e.g., SOLUMEDROL 250-500mg + 500 mL of NS once daily for several days)
  • consider the use of anxiolytics
  • a short-acting benzodiazepine (such as midazolam) and opioids should be administered before every invasive procedure
Thromboembolism prevention
  • intermittent pneumatic compression (IPC)   Intermittent pneumatic compresion (Venaflow) used in prevention of venous thromboembolism (VTE)
  • use LMWH only after securing the ruptured aneurysm

→ see here

  • hemostyptics reduce the incidence of bleeding but increase the risk of ischemia
  • the should only be used in proven hypocoagulable states
etamsylate (DICYNONE)  500 mg IV every 6-8 hours
  • fever is expected in the first days after SAH (due to neurogenic dysregulation, the presence of blood in the cerebrospinal fluid)
  • infectious complications are common in the later phase
    • monitor CRP and procalcitonin levels
  • treatment is focused on maintaining normothermia
Epileptic seizures
  • seizures increase intracranial hypertension and the risk of rebleeding
  • prophylactic administration of anticonvulsant medication can be considered for a few days in the acute phase, at least until the aneurysm is secured

→ Acute symptomatic seizures

  • Hb < 90 g/L (< 100 g/L for vasospasms) is a predictor of a poor outcome
  • however, since transfusion can also worsen prognosis, individual assessment is essential

Laboratory studies and other methods

  • serum chemistry panel –  a baseline for detecting future complications
    • natremia should be checked repeatedly
  • CBC – evaluates potential infection or hematologic abnormalities
  • prothrombin time (PT) and activated partial thromboplastin time (aPTT) to rule out coagulopathy
  • blood typing/screening – to be ready for potential transfusion
  • cardiac enzymes, cardiac troponin
    • to exclude possible myocardial ischemia
    • predictor of pulmonary and cardiac complications
    • a correlation was found between troponin levels and neurological complications and outcome
  • arterial blood gas (ABG) – required in respiratory-compromised patients
  • a baseline chest X-ray
  • ECG + ECG monitoring, transthoracic echocardiogram
    • differentiate myocardial ischemia from common benign changes
    • patients with SAH can experience myocardial ischemia due to the increased level of circulating catecholamines or autonomic stimulation from the brain
  • nonspecific ST and T wave changes
  • decreased PR intervals
  • prolonged QRS intervals
  • prolonged QT intervals
  • presence of U waves
  • arrhythmias – premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), and bradyarrhythmias

Prevention and treatment of vasospasms

Rebleeding prevention – timing

  • rebleeding prevention is essential in SAH management – the risk is highest in the first few days (4% within the first 24 h) and decreases over time
  • risk factors for rebleeding:
    • decompensated hypertension
    • aneurysm size and shape
    • the severity of initial bleeding, incl. ICH or IVH
    • seizures
  • the most effective prevention is to treat the source ASAP (acute procedure, ideally within 24 hours) if the clinical condition of the patient permits
    • thanks to vasospasm monitoring by TCD/TCCD, surgery can be performed even after 72 hours in the absence of spasm
    • endovascular treatment is possible even in the presence of vasospasm (and can be combined with PTA/vasodilatation)
    • early intervention allows subsequent full conservative therapy to prevent cerebral vasospasms
  • indication for urgent neurosurgery:
    • acute hydrocephalus requiring EVD
    • life-threatening ICH (hematoma evacuation + aneurysm clipping)
  • deferred management (elective procedures) should be chosen in the following cases:
    • presence of vasospasms when clipping is indicated
    • severe patient condition (Hunt-Hess IV-V, severe comorbidities)
    • difficult, complex aneurysm
    • incomplete endovascular team (e.g., at night)
    • aneurysms where parent artery occlusion is considered
      • it is optimal to verify collateral circulation by balloon occlusion test (BTO). However, due to heparin use, it is not suitable for the acute stage of bleeding
Hunt-Hess score
I-III indication for acute intervention
IV-V the procedure is indicated in the presence of an expanding hematoma; otherwise, the indication is uncertain (the outcome of acutely operated and non-operated patients does not differ significantly)

Rebleeding prevention – methods

Content available only for logged-in subscribers (registration will be available soon)
Craniotomy and aneurysm clipping
  • the advantage of clipping is the immediate and permanent removal of the aneurysm from the circulation
  • some aneurysms are not treatable due to their shape/location
Aneurysm clipping
Aneurysm clipping, artifact from the clip on CT scan
Endovascular procedures
  • in acute SAH, coiling alone should be performed (the use of stents and diverters requires antiplatelet therapy)
    • the aneurysm sac is usually filled with detachable platinum coils that induce local thrombosis
  • it takes some time for the aneurysm to be completely removed from the circulation; partial filling of the sac may occur, and repeated embolization is sometimes necessary (perform a control vascular imaging after the procedure)
  • rebleeding rate is slightly higher than with clipping
  • this method is preferred for aneurysms with a narrow neck (ideally < 5 mm) in the posterior circulation and for patients with more severe neurological deficits, cerebral edema, or older age with comorbidities
  • the use of flow diverters, stents, or balloon-assisted coiling extends the indications for endovascular management to aneurysms with wider necks (mostly in elective procedures)  Stent and balloon assissted coiling
Aneurysm coiling
Aneurysm coiling
Deconstructive procedures
Content available only for logged-in subscribers (registration will be available soon)

Other surgical procedures

  • external ventricular drainage (EVD) for obstructive hydrocephalus + ICP monitoring
  • lumbar CSF drainage for hyporesorptive hydrocephalus, typically for 5-7 days, with the evacuation of 100-200mL of CSF per 24h
  • trepanation and insertion of a micro-sensor for ICP (ventricular, parenchymal) and/or tissue monitoring
  • ICH evacuation (combined with clipping)
  • decompressive craniectomy

Therapy results

  • effectiveness of aneurysm treatment is measured by the rebleeding rate and clinical outcome
  • ISAT (The International Subarachnoid Aneurysm Trial)  was a prospective randomized trial comparing endovascular treatment with surgical clipping
    • only patients eligible for both treatments were enrolled at centers performing both treatments (n=2143)
    • the primary endpoint was the prevention of disability (mRS 3-5) and death from SAH within one year after treatment
    • coiling was more likely to result in independent survival at 1 year than neurosurgical clipping; the survival benefit continued for at least 7 years
      • dependency or death:  23% (endovascular) vs. 30.6% (clipping), the benefit continues > 7 years
      • risk of rebleeding was relatively low but more common after coiling compared to clipping  – 1.6%  (coiling) vs. 0.7% (clipping)
      • in both groups, rebleeding occurred most frequently during the first 30 days after aneurysm treatment, and rebleeding was associated with up to 50% mortality in both groups
  • CARAT (Cerebral Aneurysm Rerupture After Treatment)
    • the rebleeding rate was higher in the embolized patients (3.4% vs. 1.3%)
    • rebleeding in coiled patients was mostly seen in angiographically incompletely filled aneurysms
  • factors leading to incomplete aneurysm occlusion are:
    • larger aneurysms (> 10 mm)
    • wide neck (> 4 mm)


  • long-term follow-up is recommended (especially in patients with incomplete occlusion)  → increased risk of recurrence or regrowth of the treated aneurysm or development of de novo aneurysm(s)
    • in the ISAT trial, the risk of recurrent aSAH from the target aneurysms in the endovascularly treated and surgically treated groups in the first 30 days after treatment was 1.9% and 0.6%, respectively
    • In the ISAT trial, the risk of recurrent SAH from the target aneurysms in the endovascularly treated and surgically treated groups at 30 days to 1 year was 0.6% and 0.4%, at 1-5 years was 0% and 0%, and at >5 years was 0.5% and 0.3%, respectively
  • incomplete aneurysm occlusion
    • associated with a higher risk of rerupture (however, even completely obliterated aneurysms carry a risk of rerupture in the long term)
    • a higher rate of incomplete occlusion is associated with coiling compared to clipping
    • imaging (perioperative and long-term) is recommended to evaluate for remnants or recurrence that may require treatment
  • de novo aneurysm formation
    • risk is approx. 0.3% at 1-5 years, and 0.3% at >5 years
    • risk factors include younger age, family history, and multiple aneurysms
    • risk factors for growth and rupture of de novo aneurysms include female sex, shorter interval to formation of the de novo aneurysm, multiple aneurysms, and larger size

You cannot copy content of this page

Send this to a friend
you may find this topic useful:

Management of subarachnoid hemorrhage